![](/img/cover-not-exists.png)
Pr4 ISEL: A Phase III survival study comparing gefitinib (IRESSA) plus best supportive care (BSC) with placebo plus BSC, in patients with advanced non-small-cell lung cancer (NSCLC) who had received one or two prior chemotherapy regimens
Thatcher, N., Chang, A., Parikh, P., Pemberton, K., Archer, V.Volume:
49
Language:
english
Journal:
Lung Cancer
DOI:
10.1016/s0169-5002(05)80130-8
Date:
July, 2005
File:
PDF, 138 KB
english, 2005